FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077776680> ?p ?o ?g. }

• W2077776680 abstract "The PTEN and p53 tumor suppressors are the most commonly altered genes in human cancer, including prostate cancer (PCa). Loss of PTEN is associated with increased Gleason score and clinical recurrence, and the majority of human metastatic PCas have PTEN loss via multiple mechanisms. Mice with prostate-specific homozygous deletion of PTEN develop invasive PCa albeit with prolonged latency of 6-8 months. Combined PTEN/p53 inactivation in mouse prostate elicits invasive cancer by 9 weeks of age and invariable lethality by 6 months of age. Since PTEN loss results in PI3K/mTOR pathway activation, we evaluated the impact of GSK458 (PI3K/mTOR inhibitor) and GSK418 (PI3K beta/delta isoform-specific inhibitor), singly and in combination with GSK212 (MEK inhibitor), in uncastrated, prostate-specific PTEN/p53 double knockout mice (4-6 months) and PTEN mice (11-14 months), respectively, harboring advanced PCa. The drugs were administered by daily oral gavage for 3 weeks with serial 18FDG-PET/MRI imaging at baseline, 2 days, 1 week, 2 weeks and 3 weeks post-treatment respectively. GSK458 treatment of PTEN/p53 and PTEN mice results in reduction in FDG-PET uptake as early as 24 h post-treatment, with 40% tumor shrinkage by 1 week post-treatment, but rapid regrowth of 18FDG-avid tumor by 2-3 weeks post-treatment. This acquired resistance was found to be mediated in part through upregulation of multiple receptor tyrosine kinases. In contrast, PTEN/p53 and PTEN mice did not respond to GSK418, by either FDG-PET or MRI analysis. We observed increased pERK/total ERK ratio by Western blot analysis and increased p-ERK staining by immunohistochemistry in GSK458 and GSK418-treated PTEN/53 mice, respectively. Treatment of PTEN/p53 and PTEN mice with GSK212 resulted in an approx. 40% reduction in tumor volume over 3 weeks. Treatment of PTEN/p53 mice with a combination of GSK458 plus GSK212 resulted in approx. 60% reduction of tumor volume at 3 week post-treatment. Strikingly, treatment of prostate-specific PTEN only mice with GSK458 plus GSK212 combination resulted in a >90% tumor regression at 3 weeks post-treatment. These results demonstrate the potential utlitity of PI3K/MEK-directed combination therapies in the neoadjuvant setting for locally advanced disease or hormone-sensitive phase in metastatic disease, thus delaying the need for hormone ablative therapy and its associated morbidity in advanced PCa. The data underscore the value of genetically engineered mouse models to co-clinically evaluate biomarkers of response and resistance to targeted therapies, and elucidate mechanisms of acquired resistance early in clinical development. The design of “personalized” combination therapies to overcome resistance to PI3K/MEK-directed therapies in the hormone-naive and castration-resistant contexts are currently underway in multiple GEMMs and Phase Ib co-clinical trials in advanced PCa.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-365. doi:1538-7445.AM2012-LB-365" @default.
• W2077776680 created "2016-06-24" @default.
• W2077776680 creator A5009826873 @default.
• W2077776680 creator A5032556314 @default.
• W2077776680 creator A5045415451 @default.
• W2077776680 creator A5046795494 @default.
• W2077776680 creator A5057032257 @default.
• W2077776680 creator A5067823263 @default.
• W2077776680 creator A5068014441 @default.
• W2077776680 creator A5074948162 @default.
• W2077776680 creator A5079462145 @default.
• W2077776680 date "2012-04-15" @default.
• W2077776680 modified "2023-10-18" @default.
• W2077776680 title "Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer" @default.
• W2077776680 doi "https://doi.org/10.1158/1538-7445.am2012-lb-365" @default.
• W2077776680 hasPublicationYear "2012" @default.
• W2077776680 type Work @default.
• W2077776680 sameAs 2077776680 @default.
• W2077776680 citedByCount "0" @default.
• W2077776680 crossrefType "proceedings-article" @default.
• W2077776680 hasAuthorship W2077776680A5009826873 @default.
• W2077776680 hasAuthorship W2077776680A5032556314 @default.
• W2077776680 hasAuthorship W2077776680A5045415451 @default.
• W2077776680 hasAuthorship W2077776680A5046795494 @default.
• W2077776680 hasAuthorship W2077776680A5057032257 @default.
• W2077776680 hasAuthorship W2077776680A5067823263 @default.
• W2077776680 hasAuthorship W2077776680A5068014441 @default.
• W2077776680 hasAuthorship W2077776680A5074948162 @default.
• W2077776680 hasAuthorship W2077776680A5079462145 @default.
• W2077776680 hasConcept C121608353 @default.
• W2077776680 hasConcept C126322002 @default.
• W2077776680 hasConcept C143998085 @default.
• W2077776680 hasConcept C190283241 @default.
• W2077776680 hasConcept C2776235491 @default.
• W2077776680 hasConcept C2777609662 @default.
• W2077776680 hasConcept C2780192828 @default.
• W2077776680 hasConcept C502942594 @default.
• W2077776680 hasConcept C55493867 @default.
• W2077776680 hasConcept C71924100 @default.
• W2077776680 hasConcept C86554907 @default.
• W2077776680 hasConcept C86803240 @default.
• W2077776680 hasConceptScore W2077776680C121608353 @default.
• W2077776680 hasConceptScore W2077776680C126322002 @default.
• W2077776680 hasConceptScore W2077776680C143998085 @default.
• W2077776680 hasConceptScore W2077776680C190283241 @default.
• W2077776680 hasConceptScore W2077776680C2776235491 @default.
• W2077776680 hasConceptScore W2077776680C2777609662 @default.
• W2077776680 hasConceptScore W2077776680C2780192828 @default.
• W2077776680 hasConceptScore W2077776680C502942594 @default.
• W2077776680 hasConceptScore W2077776680C55493867 @default.
• W2077776680 hasConceptScore W2077776680C71924100 @default.
• W2077776680 hasConceptScore W2077776680C86554907 @default.
• W2077776680 hasConceptScore W2077776680C86803240 @default.
• W2077776680 hasLocation W20777766801 @default.
• W2077776680 hasOpenAccess W2077776680 @default.
• W2077776680 hasPrimaryLocation W20777766801 @default.
• W2077776680 hasRelatedWork W1602913332 @default.
• W2077776680 hasRelatedWork W1993312761 @default.
• W2077776680 hasRelatedWork W2098482544 @default.
• W2077776680 hasRelatedWork W2104746018 @default.
• W2077776680 hasRelatedWork W2312375518 @default.
• W2077776680 hasRelatedWork W2319211179 @default.
• W2077776680 hasRelatedWork W2744966301 @default.
• W2077776680 hasRelatedWork W3015866552 @default.
• W2077776680 hasRelatedWork W3192317526 @default.
• W2077776680 hasRelatedWork W4361817226 @default.
• W2077776680 isParatext "false" @default.
• W2077776680 isRetracted "false" @default.
• W2077776680 magId "2077776680" @default.
• W2077776680 workType "article" @default.